Skip to content

Mobile App-Supported HPV and Breast Cancer Awareness Program

The Impact of a Mobile App-Supported Human Papilloma Virus and Breast Cancer Program on HPV Literacy and Breast Cancer Screening Beliefs

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07471113
Enrollment
70
Registered
2026-03-13
Start date
2025-11-02
Completion date
2026-01-02
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Human Papilloma Virus, Women

Keywords

Human Papilloma Virus, Breast Cancer, Cervical Cancer, Nursing

Brief summary

The goal of this study is to learn about the impact of a mobile application-supported education program on women's HPV literacy and their beliefs regarding breast cancer screening. The main questions it aims to answer are: * Does a mobile application-supported program increase HPV literacy levels among women? * Does this intervention strengthen women's positive beliefs and attitudes toward breast cancer screening? Researchers will examine how this holistic, health-based intervention changes participants' awareness and screening perspectives. Participants will: * Use a mobile application designed to provide education on HPV and breast cancer * Complete surveys regarding their HPV knowledge and breast cancer screening beliefs before and after the program * Engage with health-related content through the mobile platform for the duration of the study.

Detailed description

This study aims to evaluate the effect of a mobile application-supported Human Papillomavirus (HPV) and breast cancer program on HPV literacy and breast cancer screening beliefs among women attending primary health care services.

Interventions

BEHAVIORALmobile application

A mobile application will be implemented for this group.

Sponsors

Ataturk University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
30 Months to 65 Months
Healthy volunteers
Yes

Inclusion criteria

* -Women aged 30-65 years * -Literate (able to read and write) * -Able to understand and speak Turkish * -Able to use a smartphone * -Willing to use the mobile application during the study period and consent to data sharing

Exclusion criteria

* Having undergone regular breast cancer (mammography) and/or cervical cancer (Pap smear/HPV DNA test) screening within the last 3 years, in accordance with national screening guidelines * Previous diagnosis of any cancer * Neurological conditions affecting cognitive function (e.g., dementia, Alzheimer's disease) or physical/psychiatric conditions that would seriously limit study participation and mobile app use * Pregnancy or breastfeeding * Participation in another health-related research study during the study period

Design outcomes

Primary

MeasureTime frameDescription
Change in HPV literacy (HPV-LS total score) from baseline (pretest) to post-intervention (posttest) compared between the Mobile Application-Supported Education Group and the Control Group.12 MONTHThe primary outcome is the change in participants' HPV literacy as measured by the HPV Literacy Scale (HPV; 24 items, 5-point Likert). Total scores range from 24 to 120, with higher scores indicating higher HPV literacy. The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.
Change in breast cancer screening beliefs (Breast Cancer Screening Beliefs Scale total score and/or subscale scores) from baseline to post-intervention compared between groups.12 MONTHBreast Cancer Screening Beliefs: The primary outcome is the change in breast cancer screening beliefs measured by the Breast Cancer Screening Beliefs Scale (13 items, 5-point Likert; transformed scoring 0-100). Higher scores indicate more positive screening beliefs (more favorable attitudes/knowledge and fewer perceived barriers). The outcome will be assessed at baseline (pretest) and post-intervention (posttest) and compared between groups.

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORNihan Türkoğlu

Ataturk University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026